Pharmafile Logo

Diabets

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE

New drugs drive Novo Nordisk despite insulin price pressures

Sales growth of new products up in Q4 but trouble forecasted this year

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

Novo Nordisk shareholder revolt reaches Europe

Accused of lacking transparency over pricing pressures

- PMLiVE

Novo Nordisk boosted by new type 2 diabetes launches

Rapid uptake of newcomer Ozempic aids growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links